Consumer Issues Solving Issues Related to Improving Access to Healthcare
Efforts to Solve Issues Related to Improving Access to Healthcare
In the Sustainable Development Goals (SDGs) established by the United Nations in 2015, one of the goals is to "Ensure healthy lives and promote well-being for all at all ages." Under its corporate philosophy that states, "We contribute to the healthier lives of people around the world through the creation of pharmaceuticals," the Group has contributed to society by providing treatment methods mainly using pharmaceuticals.
However, there are still many intractable diseases for which a cure has yet to be found and difficult-to-cure diseases. The mission of drug discovery companies is to continuously create new drugs that meet unmet medical needs. In addition, there are many people in the world who cannot obtain the necessary pharmaceuticals and medical services, especially in developing countries, due to inadequate healthcare systems, poverty, and disasters. To contribute to the health of people around the world and continue to meet patient needs, the Group will promote innovation, build a stable pharmaceutical distribution system, and work to solve the issue of improving access to medicine and healthcare through initiatives and patient support programs based on collaborative activities with various partners.
To continually discover innovative new drugs that address unmet medical needs such as rare and intractable diseases, we are advancing "R&D process reforms" and conduct discovery research with a focus on "expansion of medical and discovery technologies."
- Refractory disease initiatives Example: amyotrophic lateral sclerosis (ALS)
- Promoting open innovation (collaboration with academia, pharmaceutical companies, and GHIT Fund)
For details, please see "Research & Development"
Creating a Stable Drug Distribution System (Supply Chain Management)
As a pharmaceutical company, Mitsubishi Tanabe Pharma is working to steadily and accurately provide high-quality pharmaceuticals, when they are needed and to the patients who need them. In the manufacturing of pharmaceuticals, we draw on the wide range of technologies and original know-how that we have developed over many years as a global pharmaceutical enterprise.
We have built a supply system that can provide a stable supply of drugs to patients, even in the event of a disaster or other unexpected situation. At the same time, to deliver pharmaceuticals that maintain their quality to patients, we have also created a system to prevent the mixing of counterfeit pharmaceuticals and the distribution of pharmaceuticals of suspect quality including counterfeit pharmaceuticals.
For details, please see "Manufacturing and Supply Chain"
Improving Access to Pharmaceuticals and Healthcare Services
Patents in countries where access to healthcare is difficult
Under its corporate philosophy, the Mitsubishi Tanabe Pharma Group has established a policy on intellectual property that forms the basis for providing new healthcare opportunities in order to appropriately protect and make effective use of its globally competitive intellectual property. On the other hand, in countries where serious economic problems make access to healthcare difficult, we need to consider enforcing our patents rights. The Group contributes to healthcare access in economically deprived areas around the world. Therefore, as a general rule, we do not file patent applications or enforce our patent rights in the Least Developed Countries (LDCs) stipulated by the United Nations and Low-Income Countries (LICs) specified by the World Bank.
Participation in the Global Health Innovative Technology Promotion Fund
The Global Health Technology Promotion Fund (GHIT Fund), is an international public-private partnership that promotes the creation of innovative treatment agents, vaccines, and diagnostic drugs for infectious diseases that affect people in the developing world, such as malaria, tuberculosis, and neglected tropical diseases. In addition to providing financial support to the fund, we also perform joint research to create new anti-malaria drug candidate compounds through this fund and contribute to the treatment of infectious diseases in developing countries. Malaria is one of the world's three major infectious diseases, along with AIDS and tuberculosis and the eradication of malaria is a goal of the United Nations Sustainable Development Goals (SDGs).
Supporting Medical Access in Developing Countries by Donating to NPOs and NGOs
|Support provided||Description of Initiatives||Countries targeted|
|Vaccines to children in developing countries||Since 2014, Group employees have participated in vaccine support activities for children in developing countries, which are conducted by the NPO Japan Committee, Vaccines for the World's Children. This is an international contribution activity wherein donated used books and other items are sold and that amount is donated to JCV and used to deliver vaccines to children in developing countries.||Myanmar, Laos, etc.|
|Pharmaceuticals to developing countries||The Group contributes to the health of patients in developing countries who don't have access to medical care by donating its products to overseas medical volunteer NPOs operating in Africa (Kenya) and Uzbekistan.||Kenya, Uzbekistan|
|Child palliative care in developing countries||In the hope of providing palliative care services equally to all children, Mitsubishi Tanabe Pharma Indonesia matches employee donations, which it donates to the NGO Rachel House, a pioneer in palliative care in Indonesia. Through this activity, we help children suffering from serious illnesses in areas outside Jakarta where medical care is unavailable.||Indonesia|
Supporting Healthcare Services with Grants to ALS Patient Organizations
Mitsubishi Tanabe Pharma America is cooperating with "The ALS Association," an ALS patient organization, to develop various assistance activities. Specifically, the Company provides alternative communication devices, life support kits, and training and education for caregivers, and also supports patients and their families fighting intractable diseases.
Supporting ALS Patients with the Establishment of Searchlight Support
Radicava was approved as a treatment agent for amyotrophic lateral sclerosis (ALS) in the U.S. in May 2017. It has been marketed by Mitsubishi Tanabe Pharma America since August of that year. Searchlight Support was established to support ALS patients who have been prescribed Radicava. It supports patients by providing programs including treatment management tailored to each patient, insurance reimbursement support, and 24/7 clinical nursing hotline support.
Regarding these initiatives, please see "Contributions to Medical Care and Welfare"